Answers are grounded in this paper and cite their sources.
In patients with rheumatoid arthritis who had had an inadequate response to methotrexate, baricitinib was associated with significant clinical improvements as compared with placebo and adalimumab. (Funded by Eli Lilly and Incyte; ClinicalTrials.gov number, NCT01710358 .).
No takes yet. Share an insight, caveat, or question.
Taylor et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: